Fluorescence approach detects drug-resistant tuberculosis in living bacilli

Aug. 10, 2012
Scientists at the Antwerp Institute of Tropical Medicine, using an updated approach to a fluorescence technique, have succeeded in detecting drug-resistant tuberculosis (TB) in living bacilli. What's more, their technique enables detection in resource-limited locations.

Scientists at the Antwerp Institute of Tropical Medicine (ITG; Antwerp, Belgium), using an updated approach to a fluorescence technique, have succeeded in detecting drug-resistant tuberculosis (TB) in living bacilli. What's more, their technique enables detection in resource-limited locations.

Viewing sputum smears under a microscope is still the gold standard for TB screening, but it cannot differentiate between living and dead bacilli. And even though polymerase chain reaction (PCR) technology can determine whether or not the bacillus is from a resistant strain, it is unfeasible in resource-limited areas due to its cost. It also is impossible to cultivate every sample and then target it with every possible antibiotic to survey which ones still work for an individual patient.

Recognizing these limitations, lead scientist Armand Van Deun and colleagues used vital staining with fluorescein diacetate (FDA) to only stain living TB bacilli in a sputum smear, enabling them to immediately see those bacilli escaping treatment. And they improved the detection of the luminous bacilli by replacing a fluorescence microscope with an LED illumination microscope.

In this FDA test under an LED illumination microscope, the fluorescent lines are living tuberculosis bacilli on a background of cellular debris from human sputum. (Image courtesy of ITG)

The scientists' test enables detection of a high number of resistant TB bacilli that otherwise would have been discovered too late or not at all. They report that three times more patients could directly switch to the correct second-line treatment without losing time on a regimen ineffective against their resistant bacilli. And their technique can cut in half the number of cases where doctors start a retreatment because it ascertains that the bacilli detected by fluorescence microscopy in fact are dead ones, which do not require further treatment.

Together with colleagues in Bangladesh, the scientists tested their approach in the field for four years, thanks to a grant made possible by the Damien Foundation.

For more information on their work—which appears in The International Journal of Tuberculosis and Lung Disease—please visit http://dx.doi.org/10.5588/ijtld.11.0166.

-----

Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn

Laser Focus World has gone mobile: Get all of the mobile-friendly options here.

Subscribe now to BioOptics World magazine; it's free!

Sponsored Recommendations

Video: December 8, 2023 Photonics Hot List

Dec. 8, 2023
In this episode, we cover a microscopy method that hits uncharted cell territory, drone-based imaging for solar farm inspection, soliton microcombs that boost conversion efficiency...

China’s industrial laser market shows steady growth in turbulent times

Dec. 8, 2023
This in-depth market update focuses on trends in laser processing and industrial lasers while touching on what to expect in the ultrafast laser, fiber laser, LiDAR, and handheld...

What does it take to land venture capital for photonics-driven startups?

Dec. 7, 2023
Capital to grow a startup company can come from many sources: contract and non-recurring engineering (NRE) funding, angels and friends, customer upfront payments, and venture ...

Looking beyond the incremental: Reimagining optical devices

Dec. 7, 2023
Rob Devlin, co-founder and CEO of Metalenz, shares the significant people that forged his path to developing one of the most promising optics companies in the world today.

Voice your opinion!

To join the conversation, and become an exclusive member of Laser Focus World, create an account today!